It is common in clinical practice to evaluate active movement in spastic movement disorders (SMDs) associated with the upper motor neuron syndrome in terms of resistance to passive movement in the rest position, with the assumption that this may reflect motor control when the patient is in active motion. In addition, the definition of spasticity as a velocity-dependent resistance to passive movement does not account for the impact of abnormal muscle synergies (synkinesia), on active motion of upper and lower limbs in SMDs. In this article, we put forward our theory that synkinetic movement patterns are controlled by activation from spinal afferents and inhibition from the cortex, and become disturbed following a loss of inhibition and change to spinal afferents following damage to the corticospinal tract. In this regard, we propose a change in the focus from passive to active function at the evaluation stage of the SMD management plan, and a new treatment approach to modulate muscle synergies with botulinum neurotoxin type A therapy.
Cervical dystonia and spasticity are debilitating neuromuscular disorders that substantially impair quality of life. Botulinum toxin type A (BoNT-A) is a cornerstone therapy; however, heterogeneity in dosing, muscle selection, and guidance techniques can limit outcomes, and Mexico-specific practical guidance is limited. We convened a multidisciplinary panel of Mexican rehabilitation and neurology specialists with extensive experience in BoNT-A injection; recommendations were developed through a three-phase process: a targeted literature search, a structured online survey of Mexican rehabilitation and neurology specialists, and an in-person meeting (21 February 2025) where clinicians reviewed aggregated survey results and refined practical recommendations through structured deliberation. The manuscript provides pragmatic guidance on evaluation and goal setting, muscle selection, working dilutions, dosing ranges, and reinjection intervals, emphasizing ultrasound (US) and/or electromyography (EMG) for deep or high-risk targets. It also summarizes key adverse events and proposes a stepwise approach to inadequate response, prioritizing reassessment of diagnosis, goals, targeting, and techniques before considering immunogenicity testing, product switching, or alternative interventions. These recommendations aim to improve standardization, safety, and goal attainment in routine Mexican practice.